Description
Rosuvastatin & Aspirin Capsules IP are a fixed-dose combination used for the prevention of cardiovascular events such as heart attacks, strokes, and peripheral artery disease in patients with or at high risk of atherosclerotic cardiovascular disease (ASCVD). This capsule combines the lipid-lowering effect of Rosuvastatin with the antiplatelet action of Aspirin to provide synergistic protection against the progression of cardiovascular disease.
- Rosuvastatin is a high-potency statin (HMG-CoA reductase inhibitor) that significantly lowers LDL cholesterol, triglycerides, and total cholesterol, while increasing HDL cholesterol. It also stabilizes atherosclerotic plaques and has anti-inflammatory effects.
- Aspirin, in its gastro-resistant form, irreversibly inhibits platelet aggregation by blocking COX-1 enzyme and reducing thromboxane A2 production. The enteric coating helps protect the gastric mucosa from irritation.
This dual-action capsule simplifies long-term cardiovascular management in high-risk patients by reducing cholesterol levels and preventing clot formation.
Mechanism of Action:
- Rosuvastatin: Inhibits HMG-CoA reductase to reduce cholesterol synthesis and increase LDL clearance from the bloodstream.
- Aspirin: Inhibits cyclooxygenase-1 (COX-1) in platelets, preventing the formation of thromboxane A2 and reducing platelet aggregation.
Indications:
- Secondary prevention of cardiovascular events in patients with coronary artery disease, stroke, or peripheral artery disease
- Primary prevention in high-risk patients with diabetes, hypertension, or dyslipidemia
- Post-myocardial infarction, post-angioplasty, or stent placement
- Mixed dyslipidemia with concurrent risk of thrombosis
